A Deeper Look into Available and Emerging Therapies in the Management of Amyotrophic Lateral Sclerosis (ALS): Individualizing Treatment for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the Management of ALS: Leveraging Emerging Therapeutic Breakthroughs to Make Informed Decisions is a 3-part live webinar series that will provide attendees with
the latest information in the management of ALS

This is Part 3 of the series focusing on individualizing treatment for improved
clinical and economic outcomes in ALS

This activity is an archive from the webinar held January 23, 2020

This activity is valid from February 1, 2020 to February 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen and Mitsubishi Tanabe Pharma America

Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. An estimated 20,000 people in the US are living with ALS. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS, but fortunately, the treatment paradigm has expanded in recent years, giving healthcare professionals many more options in managing symptoms and delaying progression.

Upon completion of this activity, participants will be able to:

  • Examine the pathophysiology and degenerative effects of amyotrophic lateral sclerosis (ALS)

  • Discuss the impact, direct and indirect costs, and unmet needs of ALS and the value of early diagnosis

  • Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of ALS

  • Optimize the management of symptoms associated with ALS with novel treatment strategies

  • Review recently approved therapies for ALS that are designed to slow the loss of physical function

  • Analyze the role of novel antisense oligonucleotides (ASO) in the management of ALS patients that have a mutation in the SOD1 gene

Faculty: Hiroshi Mitsumoto, MD, DSc
Wesley J Howe Professor of Neurology
Eleanor and Lou Gehrig ALS Center
Department of Neurology
Columbia University Medical Center


Dr. Mitsumoto has survey on an advisory board for Mitsubishi Tanabe Pharma America. He has received grants or research from MDA and SPF. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen and Mitsubishi Tanabe Pharma America

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue